



## Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology

May 19, 2022

REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of Endocrinology (ECE), which is being held May 21-24, 2022, in Milan, Italy.

Details of the presentations are as follows:

### 2022 European Congress of Endocrinology (ECE)

Title: *DCCR Update*  
Format: Presentation at the International Prader-Willi syndrome Meeting 2022 organized by INfoRMEd – PWS (the International Network for Research, Management and Education on adults with PWS) and the European Society of Endocrinology  
Presenter: Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators  
Date: Saturday, May 21, 2022  
Time: 12:10 – 12:30 PM CET

Title: *Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome*  
Format: E-Poster -- Programme Code: EP360 / Submission Number 2044  
Presenter: Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators

Title: *Comparison of hyperphagia and problem behaviors in participants with Prader-Willi syndrome (PWS) receiving Diazoxide Choline Extended-Release (DCCR) with matched participants in PATH for PWS (PfPWS)*  
Format: Poster -- Programme Code: P77 / Submission Number 789  
Presenter: Dr. Evelien Gevers on behalf of the DESTINY PWS Investigators and the PATH for PWS Investigators  
Date: Sunday, May 22, 2022

The copy of the posters will be available in the Investors section on the Company's website at [www.soleno.life](http://www.soleno.life) after presentation at the meeting.

### About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit [www.soleno.life](http://www.soleno.life).

### Corporate Contact:

Brian Ritchie  
LifeSci Advisors, LLC  
212-915-2578



Source: Soleno Therapeutics